Note on figures cited below. Some statistics in this article come from the V12 universe cohort (227,594 BUY filings, period through 2024). Since 2025-01-01 the live out-of-sample BUY universe (28 markets) shows a 52.96 percent win rate and a +8.59 percent mean 90-day return on 20,688 filings. See methodology for the current numbers and the STRATEGY_PROOF block for the frozen audit reference.
Regulatory writing often manages the rare feat of being both short and easy to misread. Article 19 of the EU Market Abuse Regulation, usually called MAR Article 19, is a good specimen. It looks like a disclosure rule for directors dealing in their own stock. It is that, but also more specific, more mechanical, and more unforgiving than many executives assume.
This matters because the rule sits at the junction of governance, market transparency and personal liability. A chief executive who sells shares to pay tax on a vesting event, a non-executive director whose spouse trades, or a finance director who exercises options during a closed period can all find themselves inside Article 19 territory. The paperwork is not optional, the clock is short, and national regulators have shown little appetite for "we thought HR had handled it" as a defence.
The European framework is harmonised at a high level, but local practice still matters. France is a useful case study because the Autorité des marchés financiers, the AMF, has published practical guidance and enforces MAR in a market with a large population of listed issuers. ESMA, for its part, supplies the technical standards and Q&A that make the rule operable rather than merely aspirational.
Article 19 is built on a plain market logic. If senior insiders are buying or selling securities linked to their own issuer, outside investors may want to know. Sometimes that information is useful because insiders know the business well. Sometimes it is useful because the transaction is routine and tells the market very little. MAR does not ask the market to guess which is which in advance. It requires disclosure so the market can decide.
The rule therefore focuses on who is trading and what they are trading, rather than on whether the trade looks suspicious. That is a key distinction. Article 19 is not the insider dealing prohibition. A transaction can be perfectly lawful on the merits and still be reportable under Article 19. Conversely, filing an Article 19 notice does not cleanse a trade that was executed while in possession of inside information.
The rule creates a dual reporting chain:
That architecture explains why compliance failures tend to be operational rather than conceptual. The legal test is often straightforward. The missed deadline usually comes from uncertainty over who owns the process, whether the threshold has been crossed, and whether a transaction by a spouse or family trust was picked up in time.
The details matter because Article 19 is highly technical in three places:
Most mistakes are made in one of those three.
The first question is not whether someone is an insider in the colloquial sense. It is whether they are a person discharging managerial responsibilities, or PDMR, for the issuer.
Under MAR, a PDMR is broadly either:
The first limb catches directors and supervisory board members. The second limb catches certain senior executives, often the CFO, COO, heads of major divisions, and occasionally others depending on governance structure. It is a functional test, not a vanity-title test. Calling someone "senior adviser" does not help if they in fact sit in the room where material decisions are made.
For issuers, this means maintaining an accurate PDMR list is not a clerical afterthought. It is the foundation of Article 19 compliance.
Article 19 does not stop with the PDMR. It also covers persons closely associated with a PDMR, often abbreviated as CAPs or PCAs in local practice. These include:
This is where many otherwise careful insiders lose the plot. The CFO may know not to trade during a closed period. The family investment vehicle may not. The director may understand the notification form. The spouse's broker certainly does not. MAR nevertheless treats these transactions as reportable because the market effect is similar.
Article 19 is not limited to ordinary shares. It extends to:
The delegated regulation and ESMA guidance make clear that reportable transactions include a wide range of events: acquisitions, disposals, subscriptions, exchanges, pledges, lending, gifts, inheritances in some circumstances, option exercises, and transactions carried out under life insurance policies where the investment risk is borne by the policyholder and they have power to make investment decisions.
That breadth is intentional. If the instrument changes the economic exposure of the PDMR or closely associated person to the issuer, assume Article 19 may be interested.
A common misunderstanding is that equity compensation events are "internal" and therefore outside the rule. They are not. Grants, vestings, exercises, sales to cover taxes, and transfers into or out of plan structures can all be in scope depending on the facts and the implementing standards.
The practical lesson is dull but useful: HR, legal, company secretariat and the broker administering the plan must all be aligned on reporting triggers. Dull systems work. Heroic memory does not.
The phrase most often quoted from Article 19 is "EUR 5,000". It is also the phrase most often quoted incompletely.
Article 19(8) sets the threshold at EUR 5,000 within a calendar year. However, national competent authorities may decide to increase that threshold to EUR 20,000 and must inform ESMA of that decision. France has done so. For issuers under AMF supervision, the practical threshold is therefore EUR 20,000, not EUR 5,000.
That is not a drafting curiosity. It changes the filing burden materially for lower-value transactions, especially under employee share plans.
The threshold is calculated by aggregating all transactions carried out for the account of the PDMR or closely associated person in the relevant calendar year. Several points matter:
This last point deserves attention. The threshold is not a group family allowance. The PDMR has a threshold. The spouse has a threshold. A controlled legal entity may have its own analysis, depending on how the transactions are attributed and reported. The issuer should not guess. It should document the approach and apply it consistently.
Suppose a French-listed issuer is supervised by the AMF, so the threshold is EUR 20,000.
The market often finds this rule mildly absurd when a tiny fourth-quarter transaction must be disclosed because of a threshold crossed months earlier. MAR is not especially concerned with aesthetic coherence.
Even where no filing is yet required, issuers should ask PDMRs and closely associated persons to pre-clear and log in-scope transactions from the start of the year. Otherwise the company learns about the threshold crossing only after it has already missed the deadline.
That is the operational point hidden inside the legal rule. You cannot comply with a cumulative threshold if you only collect information once the threshold has been crossed.
The deadline is short enough to punish hesitation and long enough to create false confidence. Article 19 requires notification within three business days of the transaction.
The PDMR or closely associated person must notify:
The issuer must then ensure the information is made public promptly and no later than three business days after the transaction.
In practice, many issuers in France and elsewhere facilitate or coordinate the filing. Some prepare the standard form for the insider to sign or submit. That is sensible, but it does not transfer the legal obligation away from the PDMR or closely associated person. Shared process is not shared liability.
The relevant date is generally the date on which the transaction is executed, not the settlement date. For market trades, that is usually straightforward. For employee plans, option exercises, gifts, or transactions under managed arrangements, the correct date can be less obvious. ESMA's implementing standards and Q&A are the place to check, not office folklore.
Commission Implementing Regulation (EU) 2016/523 sets out the standard form and template for notifications under Article 19. The form requires details such as:
This standardisation is useful because it makes public disclosures comparable. It is also useful because incomplete forms are one of the easiest ways to turn a timely filing into a defective one.
| Market | Regulator | Rule | Deadline | Notes |
|---|---|---|---|---|
| FR | AMF | MAR Art 19 | T+3 | France applies the higher annual threshold option of EUR 20,000 and uses AMF reporting channels for managers' transactions. |
| EU general | National competent authority | MAR Art 19 | T+3 | Default annual threshold is EUR 5,000 unless the national authority has raised it, up to EUR 20,000, and notified ESMA. |
The phrase "three business days" sounds forgiving until a trade is executed on a Thursday before a public holiday. Issuers should therefore define:
Most Article 19 failures are not legal mysteries. They are workflow failures in respectable clothing.
Article 19 contains a second rule that is often confused with the first. Separate from the disclosure obligation, a PDMR must not conduct transactions on their own account or for the account of a third party, directly or indirectly, during a closed period of 30 calendar days before the announcement of an interim financial report or a year-end report which the issuer is obliged to make public.
If you are a PDMR, the default position is simple: do not trade in the 30 days before results. If you do trade, there had better be a valid exception and proper internal approval.
This is not merely a best-practice blackout policy. It is a MAR prohibition, although issuers often overlay stricter internal dealing codes.
MAR permits the issuer to allow trading during a closed period in limited circumstances, notably:
The delegated regulation, particularly Commission Delegated Regulation (EU) 2016/522, adds detail on what may count as exceptional circumstances and on the types of transactions that may be permitted. "I had planned to diversify" is not exceptional. "I need liquidity to meet a legally enforceable financial commitment that cannot reasonably be met otherwise" is closer to the intended category.
This is where people conflate two separate questions:
A permitted trade during a closed period can still be reportable. Approval to trade is not a waiver of disclosure. Compliance teams should treat the two analyses separately and document both.
The AMF's public materials on managers' transactions and issuer obligations repeatedly stress timely reporting and the importance of robust internal procedures. The French market's practical lesson is not exotic. Keep a current PDMR list, identify closely associated persons, require pre-clearance, monitor thresholds, and centralise filing responsibility. The law is European. The embarrassment is local.
Article 19 is not a ceremonial filing rule. National regulators can investigate failures to notify, late notifications, incomplete disclosures, and breaches of the closed-period restriction. Sanctions vary by jurisdiction but can include administrative fines, public censure, and, in serious cases involving related misconduct, broader enforcement consequences.
Regulators usually care about three things:
A single late filing may be treated differently from a pattern of weak controls. But repeated "administrative oversights" tend to attract scepticism. They should.
Because the issuer must make the information public within the same outer deadline, the company cannot shrug and say the executive forgot to tell us. From the regulator's perspective, that answer often confirms the control weakness rather than curing it.
That is why well-run issuers usually implement a dealing code that goes beyond the bare MAR text. Typical features include:
None of this is glamorous. Neither is enforcement correspondence.
Across markets, the same errors recur:
Companies often under-scope senior executives who regularly access inside information and influence business decisions. If the role walks like a PDMR and talks like a PDMR, the title will not save it.
Spouses, dependent children and controlled entities are the classic source of surprise filings. The surprise is usually avoidable.
It is cumulative over the calendar year, without netting. This point should be printed in large type and placed near every equity-plan administrator.
The clock generally starts on execution, not settlement.
It does not. Closed-period approval, where available, is separate from disclosure, and neither overrides the ban on trading while in possession of inside information.
For issuers supervised by the AMF or another EU competent authority, a sensible Article 19 framework usually includes:
That checklist is not exciting. It is, however, much cheaper than reconstructing who knew what on day four.
The temptation with insider transaction rules is to infer too much from the disclosure. Investors often read a director purchase as bullish and a sale as ominous. Sometimes they are right. Sometimes the sale funds tax, divorce, school fees or a portfolio rebalance. MAR does not certify motive. It standardises visibility.
It tells the market that a defined insider, or someone close to them, changed economic exposure to the issuer through a reportable transaction. That is useful information. It is not a valuation model.
It does not tell the market:
That is why serious analysis of insider transactions usually combines Article 19 disclosures with context: prior holdings, compensation structure, timing around results, and whether multiple insiders are acting in the same direction.
For insiders themselves, the reading is simpler. If you are a PDMR, or connected to one, Article 19 is not a theory exam. It is a process rule. Ask four questions before acting:
If any answer is uncertain, the correct next step is not to trade first and tidy up later. Markets have many opportunities. Filing windows have fewer.
Managers' transactions must be notified promptly and no later than three business days after the date of the transaction.
The practical burden of Article 19 is modest for firms that build a proper control framework and irritating for firms that rely on memory, spreadsheets and optimism. Regulation has a way of punishing optimism.
The concrete next step for any EU-listed issuer is straightforward: review the current PDMR list, re-notify closely associated person obligations, and test whether your filing workflow can actually produce a complete Article 19 notification and public release inside T+3 during a holiday week. The open question is not whether the rule is clear enough in principle. It is whether your process still works when the trade arrives at 5:40 pm on the day before results season begins.
Editorial note, this article was assembled without live web research (Grok unavailable in this generation pass). Evergreen sources are cited above; numerical claims are pulled from our own database snapshot as of 2026-05-17.
Our analysis of the UK market under the BUY cohort reveals a noteworthy absence of priced trades, resulting in a mean 90-day return and win rate that are not applicable. In contrast, when examining the global universe, which encompasses 227,594 BUY filings across 17 markets, we observe an aggregate mean 90-day return of -1.70% and an annualised Sharpe ratio of -0.08. These figures suggest that, despite the regulatory framework established by Article 19 of the EU Market Abuse Regulation, the effectiveness of trading strategies in this context remains questionable. The lack of positive returns and the negative Sharpe ratio indicate potential challenges in achieving market efficiency and profitability in the current environment. It is essential to note that the sample size for UK trades is insufficient, and the time horizon of 90 days may not capture longer-term market dynamics.
Last reviewed · 2026-05-18 · By Simon Azoulay · Sources, SEC EDGAR, AMF BDIF, and 28 other regulators.
The UK PDMR law retains the EU MAR framework but the FCA's enforcement style introduces distinct consequences for compli...
Insider trading disclosures are often misleading without footnotes. Learn how to interpret Form 4 filings and the signif...
France's BDIF, launched in 2009, transformed insider transaction disclosures by centralizing access, yet challenges in d...
Explore the complexities of insider transaction disclosure rules in the US and EU, highlighting differences in enforceme...
Italy's insider dealing disclosures have shifted from CONSOB to eMarket STORAGE, complicating data retrieval and histori...
This article examines the insider transaction disclosure regimes in 17 markets, highlighting differences in deadlines, p...
